Pacific Shuanglin Bio pharmacy Co Ltd (000403) - Net Assets

Latest as of March 2026: CN¥8.10 Billion CNY ≈ $1.19 Billion USD

Based on the latest financial reports, Pacific Shuanglin Bio pharmacy Co Ltd (000403) has net assets worth CN¥8.10 Billion CNY (≈ $1.19 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥9.38 Billion ≈ $1.37 Billion USD) and total liabilities (CN¥1.28 Billion ≈ $187.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Pacific Shuanglin Bio pharmacy Co Ltd (000403) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥8.10 Billion
% of Total Assets 86.37%
Annual Growth Rate 16.79%
5-Year Change 27.71%
10-Year Change 1377.61%
Growth Volatility 311.13

Pacific Shuanglin Bio pharmacy Co Ltd - Net Assets Trend (1993–2025)

This chart illustrates how Pacific Shuanglin Bio pharmacy Co Ltd's net assets have evolved over time, based on quarterly financial data. See 000403 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Pacific Shuanglin Bio pharmacy Co Ltd (1993–2025)

The table below shows the annual net assets of Pacific Shuanglin Bio pharmacy Co Ltd from 1993 to 2025. For live valuation and market cap data, see 000403 stock market capitalisation.

Year Net Assets Change
2025-12-31 CN¥8.08 Billion
≈ $1.18 Billion		 +2.07%
2024-12-31 CN¥7.92 Billion
≈ $1.16 Billion		 +6.68%
2023-12-31 CN¥7.42 Billion
≈ $1.09 Billion		 +8.17%
2022-12-31 CN¥6.86 Billion
≈ $1.00 Billion		 +8.43%
2021-12-31 CN¥6.33 Billion
≈ $925.95 Million		 +554.43%
2020-12-31 CN¥966.91 Million
≈ $141.49 Million		 +20.62%
2019-12-31 CN¥801.60 Million
≈ $117.30 Million		 +29.40%
2018-12-31 CN¥619.48 Million
≈ $90.65 Million		 +10.84%
2017-12-31 CN¥558.88 Million
≈ $81.78 Million		 +2.19%
2016-12-31 CN¥546.91 Million
≈ $80.03 Million		 +4.08%
2015-12-31 CN¥525.49 Million
≈ $76.90 Million		 +14.57%
2014-12-31 CN¥458.65 Million
≈ $67.11 Million		 +30.42%
2013-12-31 CN¥351.68 Million
≈ $51.46 Million		 +22.25%
2012-12-31 CN¥287.68 Million
≈ $42.10 Million		 +1.75%
2011-12-31 CN¥282.74 Million
≈ $41.37 Million		 +3.19%
2010-12-31 CN¥274.00 Million
≈ $40.09 Million		 +99.07%
2009-12-31 CN¥137.64 Million
≈ $20.14 Million		 -22.35%
2008-12-31 CN¥177.26 Million
≈ $25.94 Million		 +1686.54%
2007-12-31 CN¥9.92 Million
≈ $1.45 Million		 +136.53%
2006-12-31 CN¥-27.16 Million
≈ $-3.97 Million		 -124.14%
2005-12-31 CN¥112.49 Million
≈ $16.46 Million		 -81.32%
2004-12-31 CN¥602.14 Million
≈ $88.11 Million		 -28.34%
2003-12-31 CN¥840.33 Million
≈ $122.97 Million		 +7.87%
2002-12-31 CN¥779.03 Million
≈ $114.00 Million		 +13.26%
2001-12-31 CN¥687.82 Million
≈ $100.65 Million		 +14.77%
2000-12-31 CN¥599.28 Million
≈ $87.69 Million		 +24.38%
1999-12-31 CN¥481.83 Million
≈ $70.51 Million		 +104.48%
1998-12-31 CN¥235.63 Million
≈ $34.48 Million		 +14.87%
1997-12-31 CN¥205.14 Million
≈ $30.02 Million		 +32.27%
1996-12-31 CN¥155.09 Million
≈ $22.70 Million		 +141.00%
1995-12-31 CN¥64.35 Million
≈ $9.42 Million		 +11.85%
1994-12-31 CN¥57.54 Million
≈ $8.42 Million		 +2.20%
1993-12-31 CN¥56.30 Million
≈ $8.24 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Pacific Shuanglin Bio pharmacy Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 242138307140.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥2.42 Billion 29.94%
Other Components CN¥5.67 Billion 70.06%
Total Equity CN¥8.09 Billion 100.00%

Pacific Shuanglin Bio pharmacy Co Ltd Competitors by Market Cap

The table below lists competitors of Pacific Shuanglin Bio pharmacy Co Ltd ranked by their market capitalization.

Company Market Cap
Guizhou Panjiang Refined Coal Co Ltd
SHG:600395
 $1.58 Billion
Grand City Properties SA
XETRA:GYC
 $1.58 Billion
J.Pond Precision Technology Co. Ltd. A
SHE:301326
 $1.58 Billion
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351
 $1.59 Billion
DTR Automotive
KO:007340
 $1.58 Billion
ManpowerGroup Inc
NYSE:MAN
 $1.58 Billion
Kraken Robotics Inc
V:PNG
 $1.58 Billion
Ningbo Haitian Precision Machinery Co Ltd
SHG:601882
 $1.58 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Pacific Shuanglin Bio pharmacy Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 7,924,650,751 to 8,088,027,471, a change of 163,376,720 (2.1%).
  • Net income of 419,266,378 contributed positively to equity growth.
  • Dividend payments of 273,799,761 reduced retained earnings.
  • Other comprehensive income decreased equity by 203,611,965.
  • Other factors increased equity by 221,522,068.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥419.27 Million +5.18%
Dividends Paid CN¥273.80 Million -3.39%
Other Comprehensive Income CN¥-203.61 Million -2.52%
Other Changes CN¥221.52 Million +2.74%
Total Change CN¥- 2.06%

Book Value vs Market Value Analysis

This analysis compares Pacific Shuanglin Bio pharmacy Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.34x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 74.69x to 1.34x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 CN¥0.15 CN¥11.38 x
1996-12-31 CN¥0.37 CN¥11.38 x
1997-12-31 CN¥0.49 CN¥11.38 x
1998-12-31 CN¥0.54 CN¥11.38 x
1999-12-31 CN¥1.07 CN¥11.38 x
2000-12-31 CN¥1.31 CN¥11.38 x
2001-12-31 CN¥1.47 CN¥11.38 x
2002-12-31 CN¥1.67 CN¥11.38 x
2003-12-31 CN¥1.73 CN¥11.38 x
2004-12-31 CN¥1.28 CN¥11.38 x
2005-12-31 CN¥-0.03 CN¥11.38 x
2006-12-31 CN¥-0.46 CN¥11.38 x
2007-12-31 CN¥-0.44 CN¥11.38 x
2008-12-31 CN¥0.00 CN¥11.38 x
2009-12-31 CN¥0.01 CN¥11.38 x
2010-12-31 CN¥0.38 CN¥11.38 x
2011-12-31 CN¥0.47 CN¥11.38 x
2012-12-31 CN¥0.43 CN¥11.38 x
2013-12-31 CN¥0.57 CN¥11.38 x
2014-12-31 CN¥0.80 CN¥11.38 x
2015-12-31 CN¥0.93 CN¥11.38 x
2016-12-31 CN¥1.04 CN¥11.38 x
2017-12-31 CN¥1.08 CN¥11.38 x
2018-12-31 CN¥1.20 CN¥11.38 x
2019-12-31 CN¥1.64 CN¥11.38 x
2020-12-31 CN¥1.97 CN¥11.38 x
2021-12-31 CN¥8.95 CN¥11.38 x
2022-12-31 CN¥9.39 CN¥11.38 x
2023-12-31 CN¥10.20 CN¥11.38 x
2024-12-31 CN¥10.85 CN¥11.38 x
2025-12-31 CN¥8.51 CN¥11.38 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Pacific Shuanglin Bio pharmacy Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 5.18%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 15.93%
  • • Asset Turnover: 0.28x
  • • Equity Multiplier: 1.17x
  • Recent ROE (5.18%) is below the historical average (527.27%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 12.98% 5.89% 0.71x 3.10x CN¥1.92 Million
1996 10.70% 11.58% 0.43x 2.13x CN¥1.09 Million
1997 10.08% 13.13% 0.40x 1.94x CN¥162.68K
1998 9.36% 11.16% 0.37x 2.29x CN¥-1.45 Million
1999 17.74% 22.91% 0.36x 2.13x CN¥34.97 Million
2000 19.79% 28.63% 0.32x 2.14x CN¥54.00 Million
2001 12.72% 18.69% 0.31x 2.22x CN¥16.87 Million
2002 6.36% 9.60% 0.30x 2.19x CN¥-25.76 Million
2003 3.29% 3.68% 0.29x 3.07x CN¥-49.06 Million
2004 -36.70% -26.74% 0.35x 3.92x CN¥-252.22 Million
2005 0.00% -89.33% 0.36x 0.00x CN¥-662.60 Million
2006 0.00% -12.92% 0.40x 0.00x CN¥-67.96 Million
2007 0.00% 5.37% 0.39x 0.00x CN¥53.17 Million
2008 15990.29% 34.90% 0.48x 961.58x CN¥201.88 Million
2009 65.22% 0.50% 0.37x 350.66x CN¥1.97 Million
2010 18.64% 5.36% 0.59x 5.90x CN¥13.55 Million
2011 20.61% 8.91% 0.48x 4.87x CN¥20.96 Million
2012 14.16% 6.93% 0.44x 4.64x CN¥9.57 Million
2013 23.40% 14.71% 0.40x 3.95x CN¥40.25 Million
2014 28.97% 25.03% 0.41x 2.82x CN¥80.23 Million
2015 15.50% 15.50% 0.40x 2.53x CN¥27.52 Million
2016 9.04% 8.93% 0.45x 2.24x CN¥-5.35 Million
2017 3.78% 3.15% 0.52x 2.31x CN¥-35.60 Million
2018 12.54% 9.30% 0.65x 2.07x CN¥16.21 Million
2019 20.05% 17.52% 0.72x 1.59x CN¥80.43 Million
2020 19.26% 17.71% 0.64x 1.71x CN¥89.43 Million
2021 6.18% 19.83% 0.28x 1.12x CN¥-241.50 Million
2022 8.55% 24.41% 0.30x 1.16x CN¥-99.62 Million
2023 8.24% 26.29% 0.27x 1.16x CN¥-130.75 Million
2024 9.41% 28.08% 0.29x 1.17x CN¥-47.14 Million
2025 5.18% 15.93% 0.28x 1.17x CN¥-389.54 Million

Industry Comparison

This section compares Pacific Shuanglin Bio pharmacy Co Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $1,972,766,812
  • Average return on equity (ROE) among peers: -2.28%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Pacific Shuanglin Bio pharmacy Co Ltd (000403) CN¥8.10 Billion 12.98% 0.16x $1.58 Billion
Shenzhen CAU Technology Co Ltd (000004) $89.81 Million 2.75% 1.57x $53.47 Million
Nanhua Bio Medicine Co Ltd (000504) $144.30 Million -93.32% 1.86x $380.55 Million
Jiangsu Sihuan Bioengineering Co Ltd (000518) $156.83 Million 24.69% 0.38x $473.06 Million
Chengzhi Shareholding Co Ltd (000990) $1.65 Billion 1.65% 0.84x $1.59 Billion
Hualan Biological EngineeringInc (002007) $550.80 Million 9.54% 0.27x $3.43 Billion
Da An Gene Co Ltd of Sun Yat-Sen University (002030) $269.70 Million 9.75% 0.10x $1.12 Billion
Shanghai RAAS Blood Products Co Ltd Class A (002252) $11.49 Billion 5.29% 0.03x $4.56 Billion
Baolingbao Biology Co Ltd (002286) $1.51 Billion 3.27% 0.28x $507.88 Million
Tibet Cheezheng Tibetan Medicine Co Ltd (002287) $1.89 Billion 15.89% 0.21x $1.66 Billion

About Pacific Shuanglin Bio pharmacy Co Ltd

SHE:000403 China Biotechnology
Market Cap
$1.58 Billion
CN¥10.82 Billion CNY
Market Cap Rank
#7167 Global
#1636 in China
Share Price
CN¥11.38
Change (1 day)
-3.07%
52-Week Range
CN¥10.50 - CN¥18.89
All Time High
CN¥49.14
Categories
Companies in China Biotechnology
About

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen… Read more